Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 27, 2026

GROUPE PARTOUCHE: Annual Income 2024/2025 - Strong results achieved through investments and arbitrage in the portfolio

View original at globenewswire.com
GROUPE PARTOUCHE: Annual Income 2024/2025 - Strong results achieved through investments and arbitrage in the portfolio Annual Income 2024/2025 Strong results achieved through investments and arbitrage in the portfolio Turnover: € 460.2 M (+6,0 %)EBITDA: € 94.4 M (+27,8 %)Current operating income: € 30.8 M (+56,6 %)Net…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Groupe Partouche plans to distribute a dividend for the 2024/2025 financial year on the rise, with amount and terms to be specified shortly and submitted to shareholder vote

    80% confidence

  • The financial structure of the Group remains healthy with leverage ratio of 2.1x and gearing ratio of 0.4x

    80% confidence

  • Groupe Partouche has cautiously maintained position adopted as of October 31, 2021 regarding uncertainties about treatment of social security contribution relief received during Covid-19 pandemic, restoring liabilities and reducing them by €12.2M

    80% confidence

  • Vichy casino renovation completion is scheduled for the end of May 2026

    80% confidence

  • First phase of Casino Partouche Cannes 50 Croisette redevelopment expected to be completed before Cannes Film Festival at end of May 2026, with all works completed by end of June 2026

    80% confidence

  • Parisian Gaming Club will relocate into Avenue de La Grande Armée building in spring of 2026 following extensive renovations

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com